📰 Acticor Biotech News
Page 2 - Acticor Biotech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Acticor Biotech. Real-time updates on events, politics, business and more.
September 14, 2023
- Clinical results from ACTISAVE phase 2/3 study now expected in the second quarter of 2024- Optimised development plan to register glenzocimab in Europe and the United States projected no later than 2028PARIS--(BUSINESS WIRE)--Regulatory News:Acticor Biotech, (ISIN: FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical s...
September 9, 2023
September 7th, 2023, the University of Birmingham and Acticor Biotech announce the full regulatory approval of LIBERATE clinical study.
August 31, 2023
Acticor Biotech announced the results of its collaboration with Brainomix Limited, to further explore the imaging datausing Artificial Intelligence from its phase 1b/2a ACTIMIS study. The ACTIMIS...
August 21, 2023
/PRNewswire/ -- DelveInsights Medical Second Opinion Market Insights report provides the current and forecast market analysis, individual leading medical...
May 26, 2023
26.05.2023 - Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announces today that it will ...
May 17, 2023
Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular
May 9, 2023
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including
May 9, 2023
/PRNewswire/ -- DelveInsights Acute Ischemic Stroke Market Insights report includes a comprehensive understanding of current treatment practices, acute...
May 9, 2023
The dynamics of the acute ischemic stroke (AIS) market are anticipated to change during the forecast period (2023-2032) owing to the improved knowledge of stroke pathophysiology, awareness of
April 26, 2023
26.04.2023 - Regulatory News: ACTICOR BIOTECH (Paris:ALACT) (FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announces today the ...